Evidence map›Paper›PMID 41145264›Full record

ReviewBMJ open2025

The patient-driven Rare Disease Research Network: turning research on its head.

Jo Balfour, Laura B Cowley, Georgina Windsor, Ellie Dalby, Miles Sibley, Amy Hunter, Rona M Smith

Abstract readReview
In one paragraph

Review in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jo BalfourCambridge Rare Disease Network, Cambridge, UK.
Laura B CowleyDepartment of Medicine, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-5598-8592
Georgina WindsorRare Disease Research Network, Cambridge, UK.
Ellie DalbyRare Disease Research Network, Cambridge, UK.
Miles SibleyPatient Experience Library, Ballymoney, Northern Ireland, UK.
Amy HunterGenetic Alliance UK, London, London, UK.
Rona M SmithDepartment of Medicine, University of Cambridge, Cambridge, UK rona.smith@nhs.net.ORCID http://orcid.org/0000-0002-7438-5156

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe vast majority of healthcare research in the UK is investigator-led. While national progress in patient and public involvement (PPI) increasingly mandates patient consultation, research questions and outcomes still frequently misalign with patient priorities. This is particularly important in rare disease research, as more than 95% of 11 000 conditions have no effective or curative treatment, and around 20% are not clinically defined, making them difficult to diagnose and manage. The unmet physical, mental and emotional needs of people living with rare diseases are immense. Extensive guidance and toolkits exist to support investigators with PPI, but none target patient communities attempting to promote their own priorities, initiate or co-lead research.

aimThis communication article introduces the newly established patient-led Rare Disease Research Network (RDRN). WHAT IS THE RDRN, AND HOW CAN IT BE USEFUL?: Launched in November 2024, the RDRN is an open-access collaborative platform designed to support patient-driven and co-produced research, connecting patient and professional partners with similar research interests. Originally conceived by an ultra-rare patient group, the network was co-produced with the rare disease community, including individuals living with rare conditions, parents, carers and charity advocates, whose lived experience and priorities shaped every aspect of its design. Supported by academic and research networks, its collaborative development ensures RDRN removes barriers to participation while complementing existing initiatives. RDRN is a novel approach to driving new impactful research by aligning investigator priorities with real-world needs and building capacity from patients outward. Rare disease communities bring lived expertise, creativity and motivation. Yet without a structured route to collaborate, their insights are often lost. RDRN offers an inclusive space, fostering new partnerships and supporting upstream collaboration. The approach enables patients to become 'research ready' and empowers them to have an active role in generating ideas and delivering research from inception, leading to innovative research and driving meaningful change in patients' lives. With further development, RDRN could present a lasting, scalable and unified model for co-designed rare disease research. By enabling trust, capacity and shared purpose, it can drive discovery, improve outcomes and build a more resilient and self-sustaining research ecosystem, underpinning key pillars of the 2021 UK Rare Diseases Framework.

Indexed as

Biomedical ResearchPatient ParticipationRare DiseasesHumansUnited KingdomCommunity-Based Participatory ResearchDigital TechnologyHealth EquityOrganisational developmentPatient ParticipationRare Diseases

Identifiers

PMID41145264
PMCPMC12570899

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.